Sharon Benzeno - 20 Nov 2025 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role
Chief Commercial Ofc Imm Med
Signature
/s/ Sharon Benzeno by Kyle Piskel, Attorney-in-Fact
Issuer symbol
ADPT
Transactions as of
20 Nov 2025
Net transactions value
-$5,679,466
Form type
4
Filing time
24 Nov 2025, 21:39:47 UTC
Previous filing
06 Mar 2025
Next filing
08 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BENZENO SHARON Chief Commercial Ofc Imm Med C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE /s/ Sharon Benzeno by Kyle Piskel, Attorney-in-Fact 24 Nov 2025 0001780854

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADPT Common Stock Options Exercise $1,125,451 +133,032 +34% $8.46 525,755 20 Nov 2025 Direct F1
transaction ADPT Common Stock Options Exercise $837,187 +68,961 +13% $12.14 594,716 20 Nov 2025 Direct F1
transaction ADPT Common Stock Sale $4,927,680 -297,925 -50% $16.54 296,791 20 Nov 2025 Direct F1, F9
transaction ADPT Common Stock Options Exercise $5,229 +834 +0.28% $6.27 297,625 21 Nov 2025 Direct F1
transaction ADPT Common Stock Options Exercise $136,463 +20,834 +7% $6.55 318,459 21 Nov 2025 Direct F1
transaction ADPT Common Stock Options Exercise $324,094 +49,480 +16% $6.55 367,939 21 Nov 2025 Direct F1
transaction ADPT Common Stock Options Exercise $249,906 +34,375 +9.3% $7.27 402,314 21 Nov 2025 Direct F1
transaction ADPT Common Stock Options Exercise $1,454,481 +119,809 +30% $12.14 522,123 21 Nov 2025 Direct F1
transaction ADPT Common Stock Options Exercise $331,749 +83,145 +16% $3.99 605,268 21 Nov 2025 Direct F1
transaction ADPT Common Stock Sale $5,216,346 -308,477 -51% $16.91 296,791 21 Nov 2025 Direct F1, F10

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADPT Stock Option (right to buy) Options Exercise $0 -133,032 -67% $0.000000 66,517 20 Nov 2025 Common Stock 133,032 $8.46 Direct F1, F2
transaction ADPT Stock Option (right to buy) Options Exercise $0 -68,961 -33% $0.000000 136,970 20 Nov 2025 Common Stock 68,961 $12.14 Direct F1, F3
transaction ADPT Stock Option (right to buy) Options Exercise $0 -834 -100% $0.000000 0 21 Nov 2025 Common Stock 834 $6.27 Direct F1, F4
transaction ADPT Stock Option (right to buy) Options Exercise $0 -20,834 -100% $0.000000 0 21 Nov 2025 Common Stock 20,834 $6.55 Direct F1, F5
transaction ADPT Stock Option (right to buy) Options Exercise $0 -49,480 -100% $0.000000 0 21 Nov 2025 Common Stock 49,480 $6.55 Direct F1, F6
transaction ADPT Stock Option (right to buy) Options Exercise $0 -34,375 -100% $0.000000 0 21 Nov 2025 Common Stock 34,375 $7.27 Direct F1, F7
transaction ADPT Stock Option (right to buy) Options Exercise $0 -119,809 -87% $0.000000 17,161 21 Nov 2025 Common Stock 119,809 $12.14 Direct F1, F3
transaction ADPT Stock Option (right to buy) Options Exercise $0 -83,145 -42% $0.000000 116,404 21 Nov 2025 Common Stock 83,145 $3.99 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.
F2 The options vested with respect to 1/4 of such shares on March 6, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F3 The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F4 The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F5 The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F6 The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F7 The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F8 The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F9 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $16.90, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F10 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.